Neurological Type Wilson’s Disease: a Case Report

被引:0
作者
Kaitlyn Alessi
Marissa DeLima
Miranda Pfautsch
Mary Ellen Shriver
Mayur S. Parmar
机构
[1] Nova Southeastern University,Dr. Kiran C. Patel College of Osteopathic Medicine
[2] Neurologic Care Center,undefined
关键词
Wilson’s disease; Copper; Penicillamine; Diagnosis; Treatment; ATP7B; Panda sign;
D O I
10.1007/s42399-021-00960-x
中图分类号
学科分类号
摘要
Wilson’s disease (WD) was defined in 1912 as a rare autosomal recessive disorder that leads to defective excretion of copper from the body. Normally, copper is absorbed in the small intestine by enterocytes and transported into the blood via ATP7A proteins. Any excess copper is directed to the liver and excreted by hepatocytes via ATP7B. However, in patients with WD, this ATP7B protein is mutated, and copper accumulates within the body, causing various symptoms. Wilson’s disease can manifest in many different ways, such as neurological, fulminant hepatic fibrosis, ophthalmic, and even psychiatric presentation types, making it difficult to diagnose. Wilson’s disease is essential in the differential diagnosis of an individual expressing neurological symptoms because it is a treatable disease that can progressively increase in severity, and if left untreated, there is a risk of permanent brain impairment. In this case report, a 32-year-old female initially presents progressively worsening dystonia symptoms of the trunk, a wing-flapping tremor, cognitive dysfunction, and dysphonia. In terms of past medical history and past surgical history, no records were available, and she had no recollection of past genetic testing or brain MRIs but claimed to be taking Cuprimine® (penicillamine), Artane (trihexyphenidyl), and oxycodone. The physician performed a physical examination and ordered a brain MRI to collect supportive evidence for the WD diagnosis. This case illustrates a classic presentation of the neurologic type WD in the context of facilitating patient education, performing thorough physical examinations, and adjusting patient treatment plans.
引用
收藏
页码:1946 / 1950
页数:4
相关论文
共 25 条
[1]  
Sapuppo A(2020)Genotype-phenotype variable correlation in Wilson disease: clinical history of two sisters with the similar genotype BMC Med Genet 21 128-77
[2]  
Pavone P(2019)Biochemical markers for the diagnosis and monitoring of Wilson disease Clinical Biochemist Reviews 40 59-137
[3]  
Praticò AD(1997)Autonomic involvement in Wilson’s disease: a study of sympathetic skin response and RR interval variation J Neurol Sci 149 131-1543
[4]  
Ruggieri M(1970)Skin pigmentation in Wilson’s disease JAMA 211 1542-17
[5]  
Bertino G(2014)Wilson’s disease: “face of giant panda” and “trident” signs together Oxford Medical Case Reports 2014 16-145
[6]  
Fiumara A(2019)Wilson’s disease: a master of disguise Parkinsonism Relat Disord 59 140-113
[7]  
Mohr I(2015)Wilson’s disease and other neurological copper disorders The Lancet Neurology 14 103-2870
[8]  
Weiss KH(2015)Wilson’s disease: a review of what we have learned World J Hepatol 7 2859-167
[9]  
Chu EC(2015)Early neurological worsening in patients with Wilson’s disease J Neurol Sci 355 162-undefined
[10]  
Chu N-S(undefined)undefined undefined undefined undefined-undefined